Illumina Names Mark Van Oene Chief Commercial Officer, Sales Leader Brings Genomics Expertise and Strong Commercial Leadership Experience to the Role

Illumina Chief Commercial Officer Mark Van Oene (Photo: Business Wire)

???pagination.previous??? ???pagination.next???

SAN DIEGO--()--Illumina, Inc. (NASDAQ: ILMN) announced today that Mark Van Oene has been named Chief Commercial Officer. Van Oene was previously Illumina’s Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016.

“Mark is a great leader for our commercial organization, possessing deep genomics expertise and over a decade of experience building and running strong sales and marketing teams,” said Francis deSouza, Illumina President and Chief Executive Officer. “As interim Chief Commercial Officer Mark has guided Illumina through two strong quarters, including the launch of NovaSeq, and laid the foundation for our future growth. I am excited to continue to work closely with Mark to expand our commercial capability as we grow in research and clinical markets around the world.”

Van Oene joined Illumina in 2006 as Regional Account Manager for Canada. In 2008, Van Oene was promoted to Senior Director of Sales for the Americas. Four years later, he was promoted to Vice President with responsibility for global sales. From 2012 through 2014, Van Oene led the team to grow revenues from $1.06B to $1.42B. In early 2014, Van Oene was named the General Manager for the Americas region, advancing to Senior Vice President in April 2016. During that time, the Americas compound annual growth rate exceeded 20%.

As Chief Commercial Officer, Van Oene will be responsible for world-wide sales, services and marketing at Illumina. He will report to President and CEO, Francis deSouza.

Van Oene earned a Bachelor of Science degree in Biochemistry from Western University in London, Ontario, Canada.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
IR@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com

Contacts

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
IR@illumina.com
or
Media:
Eric Endicott, 858-882-6822
pr@illumina.com